Custom Chemical 98% HPLC MK-0822 MK0822 Raw Powder Odanacatib CAS 603139-19-1
TDS 19 Inquiries
603139-19-1
Research Grade
99%
SHANGHAI
HORLDEN
1g/bottle
2027-09-29
Chemical,Intermediate,5-amino-1mq,SLU-PP332,Tirzepatide,Peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOdanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K.
Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis. The drug made it to phase III trials before abandoned due to increased stroke.|Odanacatib is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K, which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Cathepsin K, a tissue-specific cysteine protease that catalyzes degradation of bone matrix proteins such as collagen I/II, elastin, and osteonectin plays an important role in osteoclast function and bone resorption.CertificatesBasic Info-
Product Name:
Odanacatib
Other Name:Pentanamide,N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]-,(2S)-;(2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)[1,1′-biphenyl]-4-yl]ethyl]amino]pentanamide;Odanacatib;N1-[(1-Cyanocyclopropyl)-4-fluoro-N2-[(1S)-2,2,2-trifluoro-1-[4-methylsulfonyl]-1,1′-biphenyl-4-yl] ethyl]-L-leucinamide
CAS No.:603139-19-1
Molecular Formula:C25H27F4N3O3S
InChIKeys:InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N
Molecular Weight:525.564
Exact Mass:525.56
EC Number:1533716-785-6
UNII:N673F6W2VH
DSSTox ID:DTXSID40209075
NCI Thesaurus Code:C66981
Categories:
Characteristics-
PSA:
107
XLogP3:4.1
Density:1.4±0.1 g/cm3
Melting Point:223-224 °C
Boiling Point:681.6±55.0°C at 760 mmHg
Flash Point:366.0±31.5 °C
Refractive Index:1.563
Hazard IdentificationClassification of the substance or mixture
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H373 May cause damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P319 Get medical help if you feel unwell.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Chemical,Intermediate,5-amino-1mq,SLU-PP332,Tirzepatide,Peptide
-
Location:
9th Floor, Room 923, Building 3, Shiyuan Daguan, Xingtai 1st Street, Chanba Ecological District, Xi'an City, Shaanxi Province
-
Payment Terms:
100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Inquiry History19 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Odanacatinib
1 G Sep 6, 2026 
Germany
Odanacatib
3 G Aug 1, 2026 
United Kingdom
odanacatib
1 G Sep 1, 2026
United Kingdom
Odanacatib
2 G Aug 3, 2026
United States
odanacatib
20 G Aug 2, 2026 
Switzerland
Odanacatib
10 G Jul 31, 2026 
India
MK-0822
500 G Jul 24, 2026 
Canada
Odanacatib
1 G Sep 8, 2026
United States
Odanacatib
3 G Sep 7, 2026
United States
Odanacatib
1 G Aug 3, 2026 
Montenegro
Odanacatib
10 G Jul 22, 2026 
Australia
Odanacatib
100 G Jul 22, 2026
Australia
Odanacatib
1 G Jul 21, 2026
United States
odanacatib
1 G Sep 6, 2026
Germany
Odanacatib
1 G Aug 11, 2026 
Kazakstan
Odanacatib
1 G Aug 7, 2026
United States
odanacatib
10 G Jul 27, 2026 
Ireland
Odanacatib
5 G Jul 13, 2026
United States
Odanacatib
1 G Jul 6, 2026 Post an enquiry for this product
